Taro Pharma (TARO) Reports Q2 EPS of $3.00
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Taro Pharma (NYSE: TARO) reported Q2 EPS of $3.00, versus $3.11 reported last year. Revenue for the quarter came in at $228.8 million, versus $212.06 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- PrivateBancorp (PVTB) Tops Q4 EPS by 7c; Continues to Work Toward CIBC Merger
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!